Erfan Bashar
Back to Multiple Sclerosis

Multiple Sclerosis Treatment

Updated:
~4 min read
Last medically reviewed:
On this pageTable of contents

Educational scope notice: This is a study note for medical students, not medical advice, diagnosis, or treatment guidance. Clinical management should follow local protocols and current guidelines.

Treatment works on three levels. Relapse therapy shortens the acute inflammatory episode. Disease-modifying therapies reduce relapse frequency, slow new MRI lesion formation, and delay permanent disability. Symptomatic therapy addresses the deficits that remain. Because relapses are only the visible part while smoldering inflammation and neurodegeneration continue between attacks, disease-modifying therapy aims at the whole process rather than the episodes alone. Treatment strategy follows the 2018 ECTRIMS/EAN framework; agents approved later postdate its drug list, so per-agent dosing and monitoring follow current labels.

Treating acute relapses

The standard approach to a relapse is high-dose intravenous methylprednisolone, typically 500 or 1,000 mg daily for 3 to 5 days. Steroids suppress the acute inflammatory cascade at the blood-brain barrier, reducing edema and immune-cell entry into the nervous system. Gastric protection is co-prescribed because high-dose steroids irritate the gastric mucosa and increase acid secretion. When steroids fail to produce meaningful recovery, particularly in severe optic neuritis or myelitis, plasma exchange serves as rescue by mechanically removing circulating antibodies and inflammatory mediators.

Moderate-efficacy first-line therapies

Interferon-beta, the first approved disease-modifying therapy, shifts the immune response away from pro-inflammatory Th1 and Th17 profiles, reduces T-cell activation across the blood-brain barrier, and downregulates the adhesion molecules immune cells use to enter the nervous system. It is an injectable first-line option.

Glatiramer acetate is a mixture of synthetic polypeptides resembling myelin basic protein. It competes with myelin antigens for MHC class II binding on antigen-presenting cells and induces anti-inflammatory regulatory T cells. It is likewise an injectable first-line agent.

Dimethyl fumarate is an oral agent that activates the Nrf2 antioxidant pathway and gradually lowers lymphocyte counts. Lymphocyte monitoring matters: pronounced lymphopenia raises the risk of progressive multifocal leukoencephalopathy, so treatment is typically reconsidered when counts fall below about 0.5 times 10⁹ per liter.

Teriflunomide is an oral inhibitor of dihydroorotate dehydrogenase, an enzyme needed for de novo pyrimidine synthesis in proliferating lymphocytes. It reduces activated T- and B-cell expansion while sparing resting lymphocytes, which use the salvage pathway.

High-efficacy therapies

Natalizumab is a monoclonal antibody against alpha-4 integrin on lymphocytes, blocking their adhesion to and passage across the blood-brain barrier. It is highly effective but carries the highest risk of progressive multifocal leukoencephalopathy. Risk stratification uses JC virus antibody status, treatment duration beyond about 2 years, and prior immunosuppressant exposure, with risk exceeding 1 in 100 when all three factors combine.

Ocrelizumab depletes CD20-positive B cells while sparing stem B cells and long-term immune memory. It is the only therapy with trial evidence in both relapsing-remitting disease (the OPERA I and II trials) and primary progressive disease (the ORATORIO trial, with about a 24% reduction in confirmed disability progression).

Fingolimod, an oral sphingosine-1-phosphate receptor modulator, traps lymphocytes in lymph nodes so they cannot recirculate into the nervous system. It carries a lower but real progressive multifocal leukoencephalopathy risk.

Alemtuzumab targets CD52 on mature lymphocytes, causing profound prolonged depletion followed by immune reconstitution that is often less pro-inflammatory. Its risk profile includes secondary autoimmunity, notably thyroid disease and immune thrombocytopenia.

Escalation versus early high-efficacy treatment

Escalation starts with a moderate-efficacy first-line drug and moves to a high-efficacy agent if relapses or new MRI lesions continue. Switching from first-line therapy to natalizumab or fingolimod has been reported to cut the annualized relapse rate from about 1.2 to about 0.2 to 0.4.

Induction, or early high-efficacy treatment, skips moderate-efficacy drugs in aggressive disease, often defined as more than 2 relapses in the prior 2 years or at least 1 relapse during at least 6 months of first-line therapy. The rationale is that every relapse causes some irreversible axonal loss, so the window for tissue preservation is narrow. A patient presenting with several recent relapses and multiple enhancing lesions should start with a high-efficacy agent rather than a moderate one.

Symptomatic management

Residual symptoms need targeted therapy alongside disease modification.

  • Spasticity responds to baclofen (a GABA-B agonist in the spinal cord), tizanidine, benzodiazepines, cannabinoids, and botulinum toxin for focal spasticity.
  • Fatigue, among the most disabling symptoms, is managed with amantadine, fampridine (a potassium-channel blocker that improves conduction in demyelinated axons and can improve walking speed), modafinil, and fluoxetine.
  • Neuropathic pain responds to carbamazepine, gabapentin, pregabalin, and amitriptyline.
  • Overactive bladder is treated with anticholinergics such as tolterodine, oxybutynin, or solifenacin, with botulinum toxin injection into the detrusor for refractory cases.
  • Depression and anxiety, which have both reactive and inflammatory components, are treated with standard selective serotonin reuptake inhibitors.

Evidence anchors

Suggest a correction